Surgical management of the primary tumor in stage IV colorectal cancer: A confirmatory retrospective cohort study

Journal of Cancer

Volumn 7, Issue 7, 2016, Pages 837-845

  Ahmed, Shahid ^a,b   Leis, Anne ^b   Chandra Kanthan, Selliah ^c   Fields, Anthony ^d   Reeder, Bruce ^b   Iqbal, Nayyer ^a,b   Haider, Kamal ^a,b   Le, Duc ^a,b   Pahwa, Punam ^b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biological agents; Chemotherapy; Combination chemotherapy; Primary tumor; Stage IV colorectal cancer; Surgery; Surgical resection; Survival

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTESTINE ISCHEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; OVERALL SURVIVAL; PELVIS ABSCESS; POST TREATMENT SURVIVAL; POSTOPERATIVE HEMORRHAGE; PRIMARY TUMOR; RETROSPECTIVE STUDY; SASKATCHEWAN; SURGICAL INFECTION; SYSTEMIC THERAPY; VENOUS THROMBOEMBOLISM; VERY ELDERLY; WOUND DEHISCENCE;

EID: 84982811013     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.14717     Document Type: Article

References (18)

1. Ahmed S, Leis A, Fields A, et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: Results from a large population-based cohort study. Cancer. 2014;120:683-91.
2. Ahmed S, Shahid RK, Leis A, et al. Should non-curative resection of primary tumor be performed in patients with stage IV colorectal cancer? A systematic review & meta-analysis. Current Oncology 2013;20:e420-41.
3. Clancy C, Burke JP, Barry M, et al. A Meta-Analysis to Determine the Effect of Primary Tumor Resection for Stage IV Colorectal Cancer with Unresectable Metastases on Patient Survival. Ann Surg Oncol. 2014;21:3900-8.
4. Faron M, Pignon J, Malka D, et al. Is primary tumor resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer. 2015;51:166-76.
5. Tsang WY, Ziogas A, Lin BS, et al. Role of primary tumor resection among chemotherapy-treated patients with synchronous stage IV colorectal cancer: a survival analysis. J Gastrointest Surg. 2014;18:592-8.
6. Venderbosch S, Wilt JH, Teerenstra S, et al. Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Ann Surg Oncol. 2011;18:3252-60.
7. Hall WH. Ramachandran R, Narayan S, et el. An electronic application for rapidly calculating Charlson comorbidity socre. BMC Cancer. 2004;4:94.
8. Assersohn, L., Norman, A., Cunningham, D. et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79:1800-05.
9. Köhne, C.H., Cunningham, D., Di, C.F. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308-17.
10. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis. 2014;29:1031-42.
11. Venook AP, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/ leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32(suppl): abstLBA3
12. Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. N Engl J Med 2014;371:1609-18
13. Ahmed S, Fields A, Pahwa P, et al. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience. Clin Colorectal Cancer. 2015;14:e41-7.
14. Gooiker GA, Dekker JW, Bastiaannet E, et al. Risk Factors for Excess Mortality in the First Year After Curative Surgery for Colorectal Cancer. Ann Surg Oncol. 2012;19: 2428-34.
15. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-14.
16. Schrag D, Weiser MR, Goodman KA, Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513-8.
17. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol. 2012;30:3223-8.
18. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379-84.